Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Impact of Salvage and Bridging Therapy in Adult Patients with Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) Referred for Anti-CD19 CAR T-Cell Therapy: An Intention to Treat Analysis

Blood (2023) 142 (Supplement 1): 4875.

https://doi.org/10.1182/blood-2023-187226

Published: 2023

Journal Articles

Sequential Scmultiomics of In Vivo CAR-T Cells Allows Characterization of Transcriptional Differences between Patients, and Identifies IL10 As a Potential Mechanism of Resistance to CAR-T Cells in MM

Blood (2023) 142 (Supplement 1): 3433.

https://doi.org/10.1182/blood-2023-182887

Published: 2023

Journal Articles

Longitudinal Transcriptomic Analysis of CAR-T Cells at Single-Cell Level Allows the Identification of Molecular Mechanisms Promoting Long-Term CAR-T Cell Persistence in MM

Blood (2023) 142 (Supplement 1): 2069.

https://doi.org/10.1182/blood-2023-182933

Published: 2023

Journal Articles

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1026.

https://doi.org/10.1182/blood-2023-180828

Published: 2023

Journal Articles

CD155 on Multiple Myeloma Cells Is Epigenetically Regulated, Reduce Patients Survival and Compromises the Action of Novel Immunotherapies

Laura Martinez-Verbo, Lorea Villanueva, Pere Llinàs-Arias, Carlos Antonio García-Prieto, David Piñeyro, Aina Oliver-Caldes, Almudena García-Ortiz, Antonio Valeri, Carlos Fernández de Larrea, Joaquin Martinez-Lopez, Gerardo Ferrer, Manel Esteller

Blood (2023) 142 (Supplement 1): 6567.

https://doi.org/10.1182/blood-2023-179313

Published: 2023

Journal Articles

Identification of Molecular Mechanisms Governing CAR-T Cell Response in MM Patients Using Single Cell Transcriptomics

Blood (2022) 140 (Supplement 1): 7366–7368.

https://doi.org/10.1182/blood-2022-163082

Published: 2022

Journal Articles

Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10281–10282.

https://doi.org/10.1182/blood-2022-166764

Published: 2022

Journal Articles

Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma

Luis Gerardo Rodríguez-Lobato, Anna de Daniel i Bisbe, Natalia Tovar, Raquel Jiménez-Segura, M. Teresa Cibeira, David F. Moreno, Aina Oliver-Caldes, Alexandra Martínez-Roca, Ester Lozano, Joan Bladé Creixenti, Laura Rosinol Dachs, Carlos Fernandez de Larrea

Blood (2022) 140 (Supplement 1): 4341–4342.

https://doi.org/10.1182/blood-2022-165371

Published: 2022

Journal Articles

Genetic Disruption of Blimp-1 Drastically Augments the Persistence and Anti-Tumour Efficacy of BCMA-Targeting CAR-T Cells

Anthony M Battram, Aina Oliver-Caldes, Miquel Bosch i Crespo, Oriol Cardus, David F. Moreno, Luis Gerardo Rodríguez-Lobato, Alvaro Urbano-Ispizua, Carlos Fernandez de Larrea

Blood (2022) 140 (Supplement 1): 2360–2361.

https://doi.org/10.1182/blood-2022-162399

Published: 2022

Journal Articles

CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell

Blood (2022) 140 (Supplement 1): 10347–10349.

https://doi.org/10.1182/blood-2022-166525

Published: 2022

Journal Articles

Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia

David F. Moreno, Sara Paz, Mari-Pau Mena, Monica Lopez-Guerra, Aina Oliver-Caldes, Anthony M Battram, Luis Gerardo Rodríguez-Lobato, Natalia Tovar, M. Teresa Cibeira, Raquel Jiménez-Segura, Joan Bladé Creixenti, Laura Rosinol, Dolors Colomer, Carlos Fernandez de Larrea

Blood (2021) 138 (Supplement 1): 462.

https://doi.org/10.1182/blood-2021-147168

Published: 2021

Journal Articles

Apheresis Products from Patients with Multiple Myeloma Treated with G-CSF Are a Suitable Source of T Cells for the Production of BCMA-Targeting CAR-T Cells

Anthony M Battram, Aina Oliver-Caldés, Miquel Bosch i Crespo, María Suárez-Lledó, Miquel Lozano, Nuria Martínez-Cibrian, Joan Cid, David F. Moreno, Luis Gerardo Rodríguez-Lobato, Alvaro Urbano-Ispizua, Carlos Fernandez de Larrea

Blood (2021) 138 (Supplement 1): 480.

https://doi.org/10.1182/blood-2021-147774

Published: 2021

Journal Articles

Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Blood (2021) 138 (Supplement 1): 552.

https://doi.org/10.1182/blood-2021-148281

Published: 2021

Journal Articles

Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2837.

https://doi.org/10.1182/blood-2021-147188

Published: 2021

Journal Articles

Design and in Vitro Evaluation of a CAR-T Prototype (ARI-0003) Targeting CD123 for Acute Myeloid Leukemia

Alex Bataller Torralba, Néstor Tirado, Diego Sánchez-Martínez, Talía Velasco-Hernández, Aina Oliver-Caldés, Sandra Castaño-Díez, Francesca Guijarro, Marina Diaz-Beyá, Manel Juan, Pablo Engel, Clara Bueno, Pablo Menendez, Álvaro Urbano-Ispizua, Jordi Esteve

Blood (2021) 138 (Supplement 1): 4799.

https://doi.org/10.1182/blood-2021-153356

Published: 2021

Journal Articles

CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome

Blood (2021) 138 (Supplement 1): 735.

https://doi.org/10.1182/blood-2021-148578

Published: 2021

Journal Articles

Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol)

Blood (2018) 132 (Supplement 1): 1385.

https://doi.org/10.1182/blood-2018-99-110895

Published: 2018

NARROW

Impact of Salvage and Bridging Therapy in Adult Patients with Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) Referred for Anti-CD19 CAR T-Cell Therapy: An Intention to Treat Analysis

Sequential Scmultiomics of In Vivo CAR-T Cells Allows Characterization of Transcriptional Differences between Patients, and Identifies IL10 As a Potential Mechanism of Resistance to CAR-T Cells in MM

Longitudinal Transcriptomic Analysis of CAR-T Cells at Single-Cell Level Allows the Identification of Molecular Mechanisms Promoting Long-Term CAR-T Cell Persistence in MM

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

CD155 on Multiple Myeloma Cells Is Epigenetically Regulated, Reduce Patients Survival and Compromises the Action of Novel Immunotherapies

Identification of Molecular Mechanisms Governing CAR-T Cell Response in MM Patients Using Single Cell Transcriptomics

Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma

Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma

Genetic Disruption of Blimp-1 Drastically Augments the Persistence and Anti-Tumour Efficacy of BCMA-Targeting CAR-T Cells

CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell

Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia

Apheresis Products from Patients with Multiple Myeloma Treated with G-CSF Are a Suitable Source of T Cells for the Production of BCMA-Targeting CAR-T Cells

Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/or Refractory Multiple Myeloma

Design and in Vitro Evaluation of a CAR-T Prototype (ARI-0003) Targeting CD123 for Acute Myeloid Leukemia

CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome

Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only